Shots:

• The companies initiate the P-III SACHI trial evaluates the efficacy & safety of Orpathys + AstraZeneca’s Tagrisso vs Pt-based doublet-CT in patients with LA or metastatic EGFR mutation-positive NSCLC with MET amplification after disease progression on EGFR inhibitor therapy. The 1st patient has been dosed on Nov 22, 2021
• The 1EPs of study is m-PFS as assessed by investigators while other EPs include m-PFS assessed by IRC, m-OS, ORR, DoR, DCR, TTR & safety
• In 2011, the companies collaborated to jointly develop & commercialize savolitinib where Hutchmed will lead marketing authorization, manufacturing & supply of therapy in China & AstraZeneca is responsible for commercialization globally

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Globe Newswire